Conditional Adenovirus Vectors for Controlled Therapeutic Protein Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy approaches for diseases like cancer and lysosomal storage disorders face challenges due to toxic side effects, limited availability of therapeutic proteins, and transient therapeutic responses, particularly with IL-12 and TNF-alpha, which require controlled and conditional expression to minimize toxicity and enhance efficacy.
Innovation Solution
Development of a recombinant adenovirus vector with a conditional promoter system that allows for controlled expression of therapeutic proteins like IL-12 and TNF-alpha, using a ligand-dependent transcription factor to regulate expression, ensuring safe and targeted delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If constitutive expression of IL-12 is used in dendritic cells, then cross-priming of tumor-specific T cells is improved, but toxicity to non-target tissues increases
Solution Approach 1:
The invention changes the expression state of the IL-12 gene from constitutive to conditional by using a promoter that can be switched on or off. This allows the system to adjust the expression level parameter based on therapeutic needs, achieving high expression when beneficial and zero expression when toxic effects occur
Solution Approach 2:
The invention introduces a dynamic control system for gene expression using a switchable promoter that can transition between active and inactive states. This dynamic regulation allows the therapeutic system to adapt to changing physiological conditions and minimize harmful effects while maintaining therapeutic efficacy
2Reliability
If early IL-12 expression is initiated in the tumor lesion, then immune response is enhanced, but control over timing and level of expression is lost
Solution Approach 1:
The invention implements a feedback-controlled gene expression system where the switchable promoter responds to external signals or cellular conditions. This allows precise temporal control of IL-12 expression, initiating it at optimal times for immune response while maintaining the ability to terminate expression when no longer beneficial
3Ease of manufacture
If therapeutic proteins are expressed without conditional control, then production simplicity is maintained, but safety and targeted delivery are compromised
Solution Approach 1:
The invention introduces a promoter switch as an intermediary control element between the gene and its expression. This mediator allows simple vector construction while providing sophisticated control over therapeutic protein expression, achieving both ease of manufacture and enhanced safety through the conditional expression system
Data Source
AI summary
This invention relates to the field of therapeutics. Most specifically, the invention provides methods of generating conditionally expressing vectors for one or more immuunomodulators under the control of a gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals. These vector may be provided to treat a variety of disorders, e.g., neoplastic disorders, through direct injection or through in vitro engineered cells, such as dendritic cells.